primary prevention of coeliac disease - Associazione Italiana ...

92 RECENT ADVANCES ON GLUTEN TOXICITY
cell epitope in naïve and sensitized mice. J Exp Med 1993; 178: 1783-8.
9. Hoyne GF, Jamicki AG, Thomas WR, Lamb JR. Characterization of the
specificity and duration of T cell tolerance to intranasally administered peptides
in mice: a role for intramolecular epitope suppression. Int Immunol 1997; 9:
1165-73.
10. Steinman L. Despite epitope spreading in the pathogenesis of autoimmune
disease, highly restricted approaches to immune therapy may still succeed (with
a edge on this bet). J Autoimmun 2000; 14: 278-82.
11. Wu B, Wu J-M, Miagkov A, Adams RN, Levitsky HI, Drachman DB. Specific
immunotherapy by genetically engineered APCs: the "guided missile" strategy. J
Immunol 2001; 166: 4773-9.
12. Wang W, Uzzau S, Goldblum SE, et al. Human zonulin, a potential modulator of
intestinal tight junctions. J Cell Sci 2000; 113: 24, 4435-44.
13. Fasano A, Not T, Wang W, et al. Zonulin, a newly discovered modulator of
intestinal permeability, and its expression in coeliac disease. Lancet 2000;
355:1518-1519.
14. Clemente MG, De Virgiliis S, Kang JS, Macatagney R, Congia M, Fasano A.
New insights on celiac disease pathogenesis: gliadin-induced zonulin release,
actin polymerization, and early increased gut permeability. Gut (in press).
15. Drago S, DiPierro M, Giambelluca D, Iacono G, Catassi C, Fasano A. Gliadin
induces occludin down-regulation and tight junctions (tj) disassembly in human
intestine. 10th International Symposium on Coeliac Disease Paris (France),
June 2-5, 2002.